Nature

Targeted radiosensitisation by pegylated liposome-encapsulated 3′, 5′-O-dipalmitoyl 5-iodo-2′-deoxyuridine in a head and neck cancer xenograft model

5-Iodo-2′-deoxyuridine (IUdR) is an effective radiosensitiser but its clinical development has been limited by toxicity. Prolonged intravenous infusions of IUdR are necessary for optimal tumour uptake ...
ascopubs.org

Liposome-encapsulated doxorubicin plus paclitaxel and trastuzumab as neoadjuvant chemotherapy for operable and locally advanced breast cancer.

A single-dose, crossover, placebo- and moxifloxacin-controlled study to assess the effects of neratinib (HKI-272) on cardiac repolarization in healthy adult subjects. Background: Schedules with ...
ascopubs.org

Liposome-Encapsulated Doxorubicin in Combination With Standard Agents (cyclophosphamide, vincristine, prednisone) in Patients With Newly Diagnosed AIDS-Related Non-Hodgkin's ...

Fludarabine Plus Mitoxantrone With and Without Rituximab Versus CHOP With and Without Rituximab As Front-Line Treatment for Patients With Follicular Lymphoma To evaluate the safety and efficacy of ...
Science Daily

Research shows advantage to nanotech delivery of therapy for breast cancer brain metastases

Breast cancer brain metastases present a challenge to clinicians because there are few systemic therapies capable of crossing the blood-brain barrier to control the disease. Scientists now report ...
FierceBiotech

Insys Therapeutics Receives FDA Orphan Drug Designation for Its Liposomal Encapsulated Paclitaxel for the Treatment of Ovarian Cancer

PHOENIX, AZ, Jan 26, 2015 (Marketwired via COMTEX) -- Insys Therapeutics, Inc. INSY, +0.10% a specialty pharmaceutical company that is developing and commercializing innovative drugs and novel drug ...
The American Journal of Managed Care

CPX-351 Effective in AML, Possibly With Reduced Cardiotoxicity vs Standard Anthracyclines

Liposomal daunorubicin and cytarabine (CPX-351) was effective in relapsed acute myeloid leukemia, but long-term follow-up is needed to determine the extent of the agent's cardiotoxicity. In a study of ...
FiercePharma

Insys Therapeutics Receives FDA Orphan Drug Designation for Its Liposomal Encapsulated Paclitaxel for the Treatment of Ovarian Cancer

Insys Therapeutics, Inc. (NASDAQ: INSY), a specialty pharmaceutical company that is developing and commercializing innovative drugs and novel drug delivery systems, today announced that the U.S. Food ...